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Munich ENU project without preceding primary albu-
minuria analysis. Two lines showing increased plasma 
urea levels were chosen to clarify if severe kidney lesions 
are involved in the abnormal phenotype. This analysis 
revealed severe albuminuria in mice which are affected 
by a recessive mutation leading to increased plasma 
urea and cholesterol levels.  Conclusion: Thus, the phe-
notypic selection of ENU-induced mutants according to 
the parameter proteinuria in principle demonstrates the 
feasibility to identify nephropathy phenotypes in ENU-
mutagenized mice. 
 Copyright © 2005 S. Karger AG, Basel 
 Research on human diseases is often hindered by the 
lack of suitable laboratory animal models. Genetic engi-
neering techniques allow the defi ned alteration of the 
mouse genome, however, the resulting phenotype of the 
mutant mice cannot be predicted. A complementary 
strategy for the establishment of suitable animal models 
for human diseases consists of the production of a great 
pool of mutant mice exhibiting different phenotypes and 
the subsequent selection of relevant lines according to 
similarities in the pathologic phenotype of animal model 
and human patients  [1] . Forward genetics techniques 
subsequently identify the causative mutation in the lines 
 [2] . 
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 Abstract 
 Background/Aim: Phenotype-driven screening of a great 
pool of randomly mutant mice and subsequent selection 
of animals showing symptoms equivalent to human kid-
ney diseases may result in the generation of novel suit-
able models for the study of the pathomechanisms and 
the identifi cation of genes involved in kidney dysfunc-
tion.  Methods: We carried out a large-scale analysis of 
ethylnitrosourea (ENU)-induced mouse mutants for al-
buminuria by using qualitative SDS-polyacrylamide 
gel electrophoresis.  Results: The primary albuminuria 
screen preceded the comprehensive phenotypic muta-
tion analysis in a part of the mice of the Munich ENU 
project to avoid loss of mutant animals as a consequence 
of prolonged suffering from severe nephropathy. The 
primary screen detected six confi rmed phenotypic vari-
ants in 2,011 G1 animals screened for dominant muta-
tions and no variant in 48 G3 pedigrees screened for 
recessive mutations. Further breeding experiments re-
sulted in two lines showing a low phenotypic penetrance 
of albuminuria. The secondary albuminuria screen was 
carried out in mutant lines which were established in the 
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 N-ethyl-N-nitrosourea (ENU) has been used in vari-
ous mouse mutagenesis programs to produce random 
mutations. Specifi c pathologic phenotypes were identi-
fi ed in the offspring of the ENU-treated mice by the use 
of appropriate routine procedures allowing the screening 
of large numbers of mice for a broad spectrum of param-
eters. Successful detection of the causative mutations in 
the phenotypically altered mice has been demonstrated 
in already examined ENU-induced mutant mouse lines. 
Both ethical and economic considerations on the large 
number of animals involved in the ENU projects force 
the implementation of a high number of different pheno-
typic screens to detect as many mutants as possible 
 [1, 3] . 
 In the Munich ENU Mouse Mutagenesis Project, the 
animals are examined in various phenotypic screens to 
characterize mouse mutants with defects of diverse organ 
systems or changes in metabolic pathways  [4] . A screen-
ing profi le of clinical chemistry parameters was estab-
lished to detect deviations of normal blood substrate and 
electrolyte levels or enzyme activities. Transmission of 
the altered phenotype to the subsequent generations was 
confi rmed by breeding of the affected mice and the screen-
ing of the offspring, thereby revealing a mutation as cause 
for the aberrant phenotype  [5, 6] . 
 Nephropathies include various multifactorial disor-
ders caused by genetic and/or environmental factors. Sev-
eral monogenic disorders are known to result in progres-
sive renal insuffi ciency. Among these are glomerular 
basement membrane defects as well as tubular and inter-
stitial alterations. Once chronic renal insuffi ciency is es-
tablished, it tends to progress to end-stage kidney failure, 
which is characterized by progressive glomerulosclerosis 
irrespective of the initiating nephropathy  [7] . 
 In glomerular diseases, proteinuria appears as a con-
sequence of the pathologic transglomerular passage of 
high-molecular-weight (HMW) proteins due to the in-
creased permeability of the glomerular capillary wall and 
the impaired reabsorption by the epithelial cells in the 
proximal tubuli. The load of these proteins in the tubular 
lumen leads to the saturation of the reabsorptive mecha-
nism of the tubular cells. This results in the urinary excre-
tion of proteins including the low-molecular-weight 
(LMW) proteins, which are reabsorbed under physiolog-
ic conditions. Thus, proteinuria is used as a marker for 
the course as well as for the response to treatments in pa-
tients with glomerular diseases  [8] . In addition, protein-
uria acts as an independent risk factor for the progression 
of renal failure  [9, 10] . 
 In humans, quantitative as well as qualitative exami-
nation of urinary protein excretion is suitable to detect 
early kidney lesions  [8] . Mice physiologically excrete large 
amounts of LMW proteins with the urine (major urinary 
proteins, MUPs)  [11] . Therefore, a qualitative screen for 
albumin, an intermediate-molecular-weight (IMW) pro-
tein (  70 kDa)  [12] , was chosen to identify mutant mice 
which might represent novel nephropathy models. This 
study describes the identifi cation of albuminuric mouse 
mutants by screening a large number of ENU-muta-
genized mice as well as the intrinsic problems associated 
with this approach. 
 Materials and Methods 
 Mutagenesis and Breeding of Mice 
 In the Munich ENU Mouse Mutagenesis Project, 10-week-old 
inbred male C3HeB/FeJ (C3H) mice were injected intraperitone-
ally with ENU (3  ! 90 mg/kg in weekly intervals). The screen for 
dominant mutations was performed on G1 animals derived from 
mutagenized C3H males mated to wild-type C3H females. Inheri-
tance of the observed abnormal phenotype in the inbred C3H ge-
netic background was tested in G2 offspring from the mating of the 
affected G1 mouse exhibiting the altered phenotype and wild-type 
mice. The screen for recessive mutations was carried out on G3 
mice produced in a two-step breeding scheme from G1 males. G1 
males which were excluded to harbor dominant mutations in the 
comprehensive phenotypic mutation analysis of the Munich ENU 
project including the albuminuria analysis and the clinical chemis-
try screen were mated to wild-type C3H females for the production 
of G2 offspring. Subsequently, 6–8 G2 females were backcrossed 
to the G1 male to produce the G3 offspring of the pedigree which 
were analyzed for recessive mutations. Inheritance of the observed 
abnormal phenotype in the inbred C3H genetic background was 
tested on G4 intercross or G4  ! G3 backcross offspring after breed-
ing the G3 phenotypic variants to wild-type mice. After the identi-
fi cation of the causative mutation, the mutant lines will be desig-
nated according to the offi cial nomenclature. Mouse husbandry was 
done under a continuously controlled specifi c pathogen-free hy-
giene standard according to the FELASA protocols [http://www.
felasa.org]. Standard diet and water were provided ad libitum. All 
animal experiments were carried out under the approval of the re-
sponsible animal welfare authority. 
 Examination of Albuminuria 
 Examination of albuminuria in G1 and G3 offspring of ENU-
treated C3H mice was carried out by the qualitative analysis of 
urinary proteins using SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE). 20-  l spot urine samples were taken from the mice 
2 months post-partum and stored at –20  °  C. Urine samples were 
boiled for 10 min after 1:  2 dilution with sample buffer (62.5 m M 
Tris-HCl pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, 
5% 2-mercaptoethanol). 10   l of the samples were electrophoresed 
(25 m M Tris, 200 m M glycine, 0.1% SDS) in a Tris-HCl-polyacryl-
amide gel (4–20% gradient) using the Bio-Rad Mini Protean II sys-
tem (Bio-Rad Laboratories, Hercules, Calif., USA). Protein bands 
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were visualized by staining with Coomassie Brilliant Blue. The 
broad range SDS-PAGE standard (Bio-Rad Laboratories) was used 
as molecular weight standard for the detected bands. Wild-type 
C3H mice were used as negative controls. Stained gels were photo-
graphed and dried for documentation. 
 Evaluation of the SDS-PAGE Analysis for the Detection of 
Albuminuria 
 In mice, urine proteins indicating early glomerular lesions (al-
bumin), advanced glomerular lesions (HMW proteins) and tubular 
lesions (proteins ranging between MUPs and albumin) were identi-
fi ed by SDS-PAGE  [13] . The evaluation of the appropriate urine 
protein detection method allowing the screening of a large number 
of animals was carried out using growth hormone transgenic mice 
which were described to inevitably develop progressive kidney le-
sions including glomerulosclerosis with secondary tubulointersti-
tial lesions  [14] . SDS-PAGE urine analysis of growth hormone 
transgenic mice of two different lines and their control littermates 
resulted in the consistent detection of the development of severe 
albumin excretion in the transgenic animals. The identifi cation of 
albumin was carried out by the comparison to molecular weight 
standards. In addition, albuminuria was confi rmed by Western blot 
analysis using rabbit anti-mouse albumin antibody (Biotrend, Co-
logne, Germany) and horseradish peroxidase-conjugated swine 
anti-rabbit antibody (Dako Diagnostika, Hamburg, Germany). 
Wild-type littermates were used as negative controls. 
 Clinical Chemistry Screen 
 Blood samples from 3-month-old G1 and G3 mice fasted over-
night were obtained by puncture of the retroorbital sinus under 
ether anesthesia. Physiologic parameter values were determined in 
male and female C3H controls. Plasma from Li-heparin-treated 
blood was analyzed using an Olympus AU400 autoanalyser (Olym-
pus, Hamburg, Germany) and the adapted reagents (Olympus). 
Calibration and quality control were performed according to the 
manufacturer’s protocols. The clinical chemistry screen included 
the following plasma parameters:  substrates: creatinine, ferritin, 
glucose, total protein, total cholesterol, transferrin, triglycerides, 
urea, uric acid;  electrolytes: calcium, chloride, iron, phosphorus, 
potassium, sodium;  enzymes: alanine aminotransferase, alkaline 
phosphatase, amylase, aspartate aminotransferase, creatine kinase, 
lactate dehydrogenase, lipase. 
 Results 
 Primary Screen for Albuminuria in ENU-Induced 
Mouse Mutants 
 The primary albuminuria screen preceded the com-
prehensive phenotypic mutation analysis in a part of the 
mice of the Munich ENU Mouse Mutagenesis Project to 
avoid loss of mutant animals as a consequence of pro-
longed suffering from severe nephropathy. The search for 
mutant mice showing albuminuria was carried out on the 
inbred C3H genetic background 2 months post-partum. 
Spot urine samples were collected in the morning and 
analyzed by SDS-PAGE. The animals positive for albu-
minuria were retested in a second analysis 2 weeks later 
to confi rm the abnormal phenotype. 
 In the nearly 3 years’ examination interval (04/01–
01/04), urine samples from 3,027 animals were analyzed. 
For the search of dominant mutations, 2,011 G1 off-
spring of ENU-treated mice were screened. Nine animals 
were found to be positive in the fi rst analysis and 6 of 
them (0.3% of the analyzed mice) were confi rmed in the 
second analysis ( table 1 ). One animal showing strong al-
buminuria died after the fi rst test. The other 2 mice were 
negative in the second analysis and, therefore, were as-
sumed to harbor no mutation. Continuous albuminuria 
was found in the six confi rmed phenotypic variants by 
observing the abnormal phenotype also in urine samples 
taken before the euthanasia of the animals at different 
ages between 6 and 20 months post-partum ( fi g. 1 ). The 
6 mice with confi rmed albuminuria were derived from 5 
different mutagenized founders. 
 To avoid additional damage of the general condition 
of the six G1 phenotypic variants, we refrained from the 
recovery of blood for the comprehensive clinical chemis-
try analysis, but directly set up the confi rmation crosses 
by mating the affected mice to wild-type animals. Four 
variants produced no positive offspring, whereas two 
lines were established which transmitted the albuminuric 
phenotype to the subsequent generations. 50% phenotyp-
ic penetrance of the symptom was expected for dominant 
mutations in our breeding scheme. However, in both lines 
only 4 of 63 G2 offspring (6.4%) showed albuminuria. 
The low penetrance was also observed in the two subse-
quent generations examined in the line 32011m (4.5% 
overall penetrance) ( table 2 ). In non-albuminuric off-
Table 1. Albuminuria screen in ENU-induced mouse mutants
Screen n (m/f)a Pedigreesb Variantsc
(m/f)
Mutantsd
(m/f)
Dominant (G1) 2,011
(1,200/811)
317 6 (5/1) 2 (2/0)
Recessive (G3) 1,016
(518/498)
48 0 –
Total 3,027 365 6 2
a m/f, males/females.
b Corresponds to the number of ENU-treated founder mice used 
for the breeding of the G1 and G3 animals.
c Offspring of ENU-treated mice showing albuminuria in both 
tests in a 2-week interval.
d Variants inheriting albuminuria to subsequent generations.
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spring of the two mutant lines (line 32011m: n = 16; line 
35064m: n = 7), clinical chemistry blood analysis was car-
ried out for the search of a correlated phenotypic marker 
to detect additional mutant individuals, but no conspicu-
ous deviations were observed. 
 Six offspring per litter were obtained on average 3 
weeks post-partum in the matings of both the two mu-
tants and the four phenotypic variants. Comparable num-
bers were detected in the matings of wild-type C3H mice. 
Deviations in the sex ratio of the offspring were also not 
observed. In addition, an impaired general condition 
leading to a decreased lifetime was revealed only in 4 of 
the 14 animals exhibiting albuminuria. In total, early loss 
of mutants before the examination time point may occur 
to a certain degree, but can explain the low phenotypic 
penetrance only to a minor part. 
 For revealing recessive mutations, 1,016 G3 offspring 
were examined which were derived from 48 pedigrees. 
None was found to be positive in the fi rst analysis 2 
months post-partum. 
 Secondary Albuminuria Screen in Established ENU 
Mutant Lines 
 In the Munich ENU Mouse Mutagenesis Project, the 
clinical chemistry analysis of more than 15,000 G1 mice 
and 230 G3 pedigrees resulted in the establishment of 
mutant lines due to various blood deviations [http://www.
lmb.uni-muenchen.de/groups/mt/mainmt2.htm; Rath-
kolb et al., unpubl. results]. Two mutant lines established 
in the project without preceding primary albuminuria 
analysis which showed increased plasma urea levels were 
chosen for the secondary albuminuria screen to clarify if 
severe kidney lesions are involved in the abnormal phe-
notype of these lines. 
 Line 10068383m harboring a recessive mutation was 
established due to increased plasma urea (75–100 mg/dl) 
and cholesterol (190–300 mg/dl) levels of the affected ho-
mozygous mutant mice. In addition, the animals showed 
a decreased lifetime of about 5 months. Unaffected het-
erozygous mutant and wild-type littermates as well as 
C3H controls showed physiologic plasma levels of urea 
(25–70 mg/dl) and cholesterol (75–160 mg/dl). Heterozy-
gous mutant and wild-type littermates also were not dis-
tinguishable in the other parameters of the clinical chem-
istry blood analysis. After breeding heterozygous mutant 
mice of the line 10068383m, the urine protein analysis of 
the offspring revealed severe albumin excretion in the 
homozygous mutants ( fi g. 2 ). The results of the albumin-
uria screen were confi rmed by the preliminary pathohis-
tologic examination of kidney samples of the homozy-
 Fig. 1. SDS-PAGE albuminuria analysis of G1 offspring of ENU-
treated mice. Protein bands were visualized by staining with Coo-
massie Brilliant Blue. The broad range SDS-PAGE standard (Bio-
Rad Laboratories) was used as molecular weight standard (M) for 
the identifi cation of the albumin excretion: HMW = high-molecu-
lar-weight proteins; BSA = bovine serum albumin; LMW = low-
molecular-weight proteins. The positive analysis of the urine taken 
before the euthanasia of the six confi rmed phenotypic variants is 
shown, thereby revealing the continuous albuminuria from the on-
set 2 months post-partum until the euthanasia of the mice. Age of 
the animals in months (mo): 24768m, 18 mo; 30077f, 17 mo; 
30435m, 6 mo; 30637m, 10 mo; 32011m, 16 mo; 35064m, 20 mo. 
m = Male; f = female. Wild-type C3H samples of various age were 
used as negative controls (C). 
Table 2. Inheritance analysis of albuminuria in the offspring of the 
dominant phenotypic variants
Variant Mutanta Offspring testedb
n (m/f)
Albuminuria
n (ID)c
24768m 28 (13/15) 0
30077f 22 (11/11) 0
30435m 10 (6/4) 0
30637m 8 (4/4) 0
32011m 30 (17/13) 2 (37226f, 37324m)
37226f 13 (9/4) 1 (36198m)
37324m 10 (5/5) 1 (43006m)
36198m 24 (15/9) 0
43006m 20 (9/11) 1 (49909m)
35064m 33 (17/16) 2 (43356f, 48442f)
a Animal number of the G1 offspring of ENU-treated mice 
showing albuminuria in both tests in a 2-week interval (phenotyp-
ic variants) and the mice inheriting the albuminuria (mutants). 
m/f = Males/females. The two positive mice 30435m and 30637m 
were offspring of the same founder.
b The offspring were produced by mating the affected mice (var-
iants/mutants) to wild-type animals.
c ID = animal number of the positive mice.
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gous mutant mice where severe alterations were observed 
( fi g. 3 ). 
 Heterozygous mutant mice of a second line 
(20003171m) showed increased plasma urea levels analo-
gous to line 10068383m due to a dominant mutation. In 
addition, the clinical chemistry blood analysis of the mu-
tants showed signifi cant deviations in the parameters glu-
cose, total protein, triglycerides, alkaline phosphatase 
and amylase. No albuminuria was observed in the mutant 
mice (14 heterozygous mutants) in the secondary albu-
minuria screen. The pathohistologic analysis of the kid-
ney samples also showed no gross alterations (not 
shown). 
 Discussion 
 Qualitative SDS-PAGE analysis of urinary proteins 
resulted in the identifi cation of ENU-induced mouse mu-
tants showing the pathologic excretion of serum albumin. 
Transmission of the deviation to the subsequent genera-
tions led to the establishment of lines showing albumin-
uria. 
 Reproduction of the positive primary results in the 
subsequent tests succeeded in most of the phenotypic 
variants as well as in the examined positive offspring in 
the lines showing albuminuria. Failure of the transmis-
sion of the defect to the offspring in four of the six mated 
phenotypic variants was also found in a comparable ratio 
 Fig. 3. Histopathologic kidney analysis of 
homozygous mutant mice of the line 
10068383m harboring a recessive muta-
tion. Light microscopic aspect of kidney 
changes in an 11-week-old female homozy-
gous mutant. Severe glomerular lesions 
with obliteration of glomerular capillaries 
and proteinaceous casts in tubular lumina 
are present. Paraffi n section, hematoxylin 
and eosin stain, scale bar 50   m. Subse-
quent analyses have to be carried out to re-
veal the detailed mutant renal phenotype of 
the line. 
 Fig. 2. SDS-PAGE albuminuria analysis of line 10068383m har-
boring a recessive mutation. Protein bands were visualized by 
staining with Coomassie Brilliant Blue. The broad range SDS-
PAGE standard (Bio-Rad Laboratories) was used as molecular 
weight standard (M) for the identifi cation of the albumin excretion: 
HMW = high-molecular-weight proteins; BSA = bovine serum al-
bumin; LMW = low-molecular-weight proteins. Offspring of het-
erozygous mutants were examined and severe albuminuria was ob-
served to be strictly correlated to the homozygous mutant mice 
showing increased plasma urea and cholesterol levels (HO). Dilu-
tions of the urine of 4-week-old mice were used for the preparation 
of the fi gure. Older homozygous mutants of this line showed se-
verely increased albuminuria. W = Heterozygous mutant or wild-
type littermates showing normal plasma urea and cholesterol 
 levels. 
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for the inheritance of other phenotypic deviations in our 
clinical chemistry screen [Rathkolb et al., unpubl. re-
sults]. One reason may be the occurrence of not geneti-
cally fi xed proteinuria due to the inherent impossibility 
of carrying out complete standardization of husbandry 
and experiment. In addition, the urine of normal mice 
contains small amounts of albumin  [12] . Faint signals of 
the same molecular weight were inconsistently seen in 
unaffected mice of our study in the SDS-PAGE analysis. 
Urine albumin content in normal mice was estimated to 
correspond to 0.5–1.5 mg/dl by subsequent clinical chem-
istry urine analysis. Thus, the pathologic increase of the 
normally low albumin excretion was used as phenotypic 
marker. 
 A low phenotypic penetrance of the defect was re-
vealed in both mutant lines where 50% of the offspring 
in our breeding scheme were expected to show albumin-
uria. Appearance of albuminuria due to the interaction 
of multiple mutations leads to lower levels of affected 
offspring. In addition, variations in the concentration of 
the urine samples might infl uence the outcome of the 
screen by the failure in the detection of albuminuria 
which may be observed by measuring the albumin/cre-
atinine ratio. Alternatively, the incomplete penetrance 
might be due to the analysis of mice at an early age. The 
early examination time point was chosen to avoid loss of 
mutant animals as a consequence of prolonged suffering 
from severe albuminuria and/or nephropathy. Screening 
mice for albuminuria at an increased age might lead to a 
higher level of penetrance as well as to additional albu-
minuric phenotypes due to alternative ENU-induced mu-
tations. 
 Propagation of the mutant lines as well as the exami-
nation of the genetic cause of the aberrant phenotype are 
facilitated by a high phenotypic penetrance. The pheno-
typic analysis of the mutation may be improved by ana-
lyzing the animals more frequently, by examining mice 
with an older age and/or by searching for additional de-
viations in the clinical chemistry parameters which are 
indicative of the mutation. The standard use of albumin-
specifi c antibodies for the increase of the detection sensi-
tivity contrasts with the high throughput nature of the 
established test. Susceptibility to renal damage was found 
to be dependent on the genetic background  [15, 16] 
[http://www.jax.org/phenome; http://www.eumorphia.
org]. Therefore, generation and subsequent analysis of 
hybrids and/or congenic strains may also infl uence the 
phenotypic penetrance. 
 The strategy for the analysis of the number and the 
chromosomal position of the causative dominant muta-
tions in ENU projects consists in the establishment and 
examination of backcross matings. Briefl y, C3H pheno-
typic mutants harboring the dominant mutation are bred 
to wild-type mice of a second inbred strain, the resulting 
hybrid offspring are analyzed for the abnormal pheno-
type of the parent and hybrid phenotypic mutants are 
backcrossed to wild-type mice of the second inbred strain. 
The resulting backcross offspring are again analyzed for 
the abnormal phenotype of the parent thereby dividing 
them into mutant and non-mutant animals. Genome-
wide microsatellite linkage analysis of the DNA samples 
subsequently reveals the chromosomal position of the 
mutation, which is further analyzed by additional mo-
lecular genetic techniques. Analysis of mutant lines show-
ing incomplete penetrance of the abnormal phenotype 
requires the production and examination of a great num-
ber of offspring. Therefore, due to their low phenotypic 
penetrance, the two mutant lines established in the pri-
mary albuminuria screen may provide candidate regions 
for the renal research rather than distinct candidate 
genes. 
 Most mouse models which have been produced to date 
by genetic engineering techniques (additive gene transfer, 
gene knockout) show a lack of relevant phenotypes for 
their subsequent use in the analysis of the genetic factors 
which are involved in chronic kidney diseases  [15, 17] . 
Due to the triggering of random mutations by ENU, the 
phenotype-driven method has the impact to provide nov-
el kidney disease models  [18, 19] . 
 In summary, we showed the selection of mutant mice 
according to the symptom albuminuria and the inheri-
tance of the aberrant phenotype to subsequent genera-
tions. In addition, the screen was established for the as-
sessment of the involvement of kidney lesions to other 
mutant phenotypes prior to the detailed pathohistologic 
analysis. Both the mapping and subsequent identifi cation 
of the causative mutation and the precise pathological 
analysis of the mutation will establish unique models for 
nephropathies. 
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